Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 8;12(3):626.
doi: 10.3390/cancers12030626.

The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy

Olivia Knittelfelder  1 , Daniela Delago  1 , Gabriele Jakse  1 , Katarzyna Lukasiak  1 , Eva-Maria Thurner  1 , Dietmar Thurnher  2 , Martin Pichler  3   4 , Wilfried Renner  5 , Heidi Stranzl-Lawatsch  1 , Tanja Langsenlehner  1
Affiliations

The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy

Olivia Knittelfelder et al. Cancers (Basel). .

Abstract

The purpose of the present study was to evaluate the prognostic significance of the pre- treatment C-reactive protein (CRP) level in a cohort of 503 patients with oral and oropharyngeal cancer treated at a tertiary academic center between 2000 and 2017. Cancer-specific survival (CSS), overall survival (OS) and loco-regional control (LC) were calculated using Kaplan-Meier analysis. To evaluate the prognostic value of the CRP level for the clinical endpoints, univariate and multivariate Cox regression models were applied. The median follow-up period was 61 months. Patients were divided into elevated CRP (≥5 mg/L) and normal CRP groups, according to pre-treatment plasma levels. An increased CRP level was significantly associated with shorter CSS (p < 0.001, log-rank test), as well as with shorter OS (p < 0.001, log-rank test) and loco-regional control (p = 0.001, log-rank test). In addition, multivariate analysis identified CRP as an independent predictor for CSS (hazard ratio (HR) 1.59, 95% confidence interval (CI) 1.08-2.35; p = 0.020) as well as for OS (HR 1.62, 95%CI 1.17-2.24; p = 0.004) and LC (HR 1.50, 95%CI 1.06-2.14; p = 0.023). In subgroup analysis, Kaplan Meier curves revealed that an elevated pre-treatment CRP level was a consistent prognostic factor for poor CSS (p = 0.003, log-rank test), OS (p = 0.001, log-rank test), and LC (p = 0.028, log-rank test) in patients treated with definitive (chemo-) radiotherapy, whereas a significant association in patients undergoing surgery and postoperative radiotherapy was not detected. The pre-treatment CRP level seems to represent a prognostic factor for CSS, OS, and LC in patients with oral and oropharyngeal cancer, particularly in those treated with definitive (chemo-) radiotherapy. Additional large-scale prospective studies are warranted to confirm and extend our findings.

Keywords: C- reactive protein (CRP); biomarker; inflammation; oral and oropharyngeal cancer; outcome; prognostic factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier curves for (a) cancer-specific survival, (b), overall survival, and (c) loco-regional control categorized by the pre-treatment CRP level. Abbreviation: CRP, C- reactive protein.
Figure 2
Figure 2
Kaplan-Meier curves for (a) cancer-specific survival, (b), overall survival, and (c) loco-regional control in patients treated with definitive (chemo-) radiotherapy categorized by the pre-treatment CRP level. Abbreviation: CRP, C- reactive protein.
See this image and copyright information in PMC

References

    1. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet. 2008;371:1695–1709. doi: 10.1016/S0140-6736(08)60728-X. - DOI - PMC - PubMed
    1. Pignon J.P., le Maitre A., Maillard E., Bourhis J., Group M.-N.C. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 2009;92:4–14. doi: 10.1016/j.radonc.2009.04.014. - DOI - PubMed
    1. Misawa K., Mima M., Satoshi Y., Misawa Y., Imai A., Mochizuki D., Nakagawa T., Kurokawa T., Oguro M., Ishikawa R., et al. Neuropeptide receptor genes GHSR and NMUR1 are candidate epigenetic biomarkers and predictors for surgically treated patients with oropharyngeal cancer. Sci. Rep. 2020;10:e1007. doi: 10.1038/s41598-020-57920-z. - DOI - PMC - PubMed
    1. Lu L., Wu Y., Feng M., Xue X., Fan Y. A novel sevenmiRNA prognostic model to predict overall survival in head and neck squamous cell carcinoma patients. Mol. Med. Rep. 2019;20:4340–4348. - PubMed
    1. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539–545. doi: 10.1016/S0140-6736(00)04046-0. - DOI - PubMed